Pacira BioSciences (PCRX) Liabilities and Shareholders Equity (2010 - 2026)

Pacira BioSciences' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 23.83% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $5.3 billion (down 15.86% YoY), while the FY2025 annual figure was $1.3 billion, down 18.58% from the prior year.
• Liabilities and Shareholders Equity was $1.2 billion for Q1 2026 at Pacira BioSciences, down from $1.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.9 billion in Q1 2022 to a low of $1.2 billion in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $1.6 billion across 5 years, with a median of $1.6 billion in 2024.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity jumped 46.91% in 2022, then dropped 23.83% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.7 billion in 2022, then retreated by 6.35% to $1.6 billion in 2023, then decreased by 1.33% to $1.6 billion in 2024, then fell by 18.58% to $1.3 billion in 2025, then declined by 4.46% to $1.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.2 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.